• Spago Nanomedical will hold an extraordinary general meeting in Stockholm on November 19, 2026.
• Shareholders will vote on the board’s proposal to apply for delisting from Nasdaq First North Growth Market.
• The board expects delisting to improve access to specialist investors for funding Tumorad’s planned Phase IIa study.
• The provisional timetable targets a delisting application on January 25, 2027, with the final trading day expected in February 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spago Nanomedical AB published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.